Story perspectives

Revolutionary Heart Treatments: UConn's Genetic Engineering Breakthroughs

9/5/2025

22 3

Summary

Story summary

Dr. Travis Hinson at UConn School of Medicine is pioneering genetic engineering for heart disease, impacting 5-10% of patients.
His team develops "beating avatars" of hearts to test gene therapies, targeting human trials in five years.
Hinson critiques one-size-fits-all treatments for heart failure.
Ke Yuan's research at Boston Children's Hospital reveals a unique marker, Higd1b, for studying pericytes in pulmonary arterial hypertension.
New findings on human endogenous retroviruses (HERVs) may enable innovative diagnostics and therapies for cancer and autoimmune diseases.

1 of 1

Story summary

Dr. Travis Hinson at UConn School of Medicine is pioneering genetic engineering for heart disease, impacting 5-10% of patients.
His team develops "beating avatars" of hearts to test gene therapies, targeting human trials in five years.
Hinson critiques one-size-fits-all treatments for heart failure.
Ke Yuan's research at Boston Children's Hospital reveals a unique marker, Higd1b, for studying pericytes in pulmonary arterial hypertension.
New findings on human endogenous retroviruses (HERVs) may enable innovative diagnostics and therapies for cancer and autoimmune diseases.